11.00p-0.13 (-1.12%)17 Jan 2025, 16:27
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Angle PLC Fundamentals

Company NameAngle PLCLast Updated2025-01-17
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue322.528 mMarket Cap£35.48 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.08EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.1279Debt Equity Ratio0.1434
Asset Equity Ratio1.3459Cash Equity Ratio0.7297
Quick Ratio4.3525Current Ratio5.19
Price To Book Value1.4478ROCE0

Angle PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Angle PLC Company Financials

Assets20232022
Tangible Assets£7.23 m£8.48 m
Intangible Assets£2.74 m£2.76 m
Investments00
Total Fixed Assets£9.97 m£11.24 m
Stocks£1.68 m£2.06 m
Debtors£1.81 m£1.77 m
Cash & Equivalents£16.22 m£31.90 m
Other Assets00
Total Assets£31.18 m£49.87 m
Liabilities20232022
Creditors within 1 year£3.94 m£5.25 m
Creditors after 1 year£4.30 m£4.55 m
Other Liabilities00
Total Liabilities£8.24 m£9.80 m
Net assets£22.94 m£40.06 m
Equity20232022
Called up share capital£26.06 m£26.06 m
Share Premium£115.92 m£115.92 m
Profit / Loss-£21.63 m-£24.44 m
Other Equity£22.94 m£40.06 m
Preference & Minorities00
Total Capital Employed£22.94 m£40.06 m
Ratios20232022
Debt Ratio£0.15£0.10
Debt-to-Equity£0.17£0.11
Assets / Equity1.34591.3459
Cash / Equity0.72970.7297
EPS-£0.08-£0.09
Cash Flow20232022
Cash from operating activities-£14.46 m-£16.05 m
Cashflow before financing-£15.58 m£2.05 m
Increase in Cash-£15.79 m£295,000.00
Income20232022
Turnover£2.19 m£1.04 m
Cost of sales£658,000.00£428,000.00
Gross Profit£1.53 m£613,000.00
Operating Profit-£21.76 m-£24.21 m
Pre-Tax profit-£21.63 m-£24.44 m

Angle PLC Company Background

SectorHealthcare
ActivitiesANGLE PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.
Latest Interim Date26 Sep 2024
Latest Fiscal Year End Date5 Jun 2024

Angle PLC Directors

AppointedNamePosition
2024-06-19Mr. Garth Robert SelveyNon-Executive Director
2024-06-19Mr. Andrew David William NewlandExecutive Director,Chief Executive Officer
2014-09-30Mr. David William Quysner CBENon-Executive Director
2024-06-19Mr. Ian Francis GriffithsExecutive Director,Finance Director and Company Secretary
2024-06-19Mr. Brian HowlettNon-Executive Director,Senior Independent Director
2011-08-09Dr. Hance Fullerton OBE LLDNon-Executive Director,Chairman

Angle PLC Contact Details

Company NameANGLE PLC
Address10 Nugent Road, The Surrey Research Park, Guildford, GU2 7AF
Telephone+44 1483295830
Websitehttps://www.angleplc.com

Angle PLC Advisors

Financial PR AdviserFTI Consulting Inc
Phone+44 2037271000
Fax+44 2037271007
AuditorRSM
Phone0845 057 0700
Fax0845 057 0701
BankNational Westminster Bank PLC
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
StockbrokerCenkos Securities
Phone+44 2073978900
Fax+44 2073978901
SolicitorPinsent Masons LLP
Phone(020) 7418 7000
Fax(020) 7418 7050
Nominated AdviserCenkos Securities
Phone+44 2073978900
Fax+44 2073978901